Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Armstrong AJ, et al. Among authors: eisen t. Lancet Oncol. 2016 Mar;17(3):378-388. doi: 10.1016/S1470-2045(15)00515-X. Epub 2016 Jan 13. Lancet Oncol. 2016. PMID: 26794930 Free PMC article. Clinical Trial.
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Atkins MB, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. doi: 10.1158/1078-0432.CCR-040720. Clin Cancer Res. 2004. PMID: 15448017 Review. No abstract available.
Treatment of recurrent or metastatic renal cell carcinoma.
Shah RN, Ahmad T, Eisen TG. Shah RN, et al. Among authors: eisen tg. Expert Rev Anticancer Ther. 2004 Dec;4(6):1069-80. doi: 10.1586/14737140.4.6.1069. Expert Rev Anticancer Ther. 2004. PMID: 15606334 Review.
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Ratain MJ, et al. Among authors: eisen t. J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636341 Clinical Trial.
Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM, Eisen T. Larkin JM, et al. Among authors: eisen t. Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. doi: 10.1016/j.critrevonc.2006.06.008. Epub 2006 Jul 24. Crit Rev Oncol Hematol. 2006. PMID: 16860997 Review.
Adjuvant therapy of renal cell carcinoma.
Yap TA, Eisen TG. Yap TA, et al. Clin Genitourin Cancer. 2006 Sep;5(2):120-30. doi: 10.3816/CGC.2006.n.028. Clin Genitourin Cancer. 2006. PMID: 17026800 Review.
Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Escudier B, et al. Among authors: eisen t. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655. N Engl J Med. 2007. PMID: 17215530 Free article. Clinical Trial.
249 results